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by Elsevier B.V. All rights reserved.Abstract Background and objectives: Metered-dose inhalers plus spacers (MDI-spacer) are as
effective as, or better than, nebulizers in aerosol delivery. The selection of aerosol delivery
system for hospitalized children can have a significant impact on the utilization of healthcare
resources.
Design and setting: A quality improvement project to evaluate the impact of conversion to
MDI-spacer to administer bronchodilators (BDs) and inhaled corticosteroids (ICSs) to hospital-
ized children on the utilization of hospital resources. The project was conducted in a tertiary
pediatric ward from April to May 2013.
Materials and methods: The project was conducted over a six-week period. In the first two
weeks, data were gathered from all hospitalized children receiving BDs and/or ICSs by nebu-
lizers. This data collection was followed by a two-week washout period during which training
of healthcare providers and operational changes were implemented to enhance the conversion
to MDI-spacer. In the last two weeks, data were gathered from hospitalized children after con-
version to MDI-spacer. The primary outcomes included the mean time (in minutes) of medica-
tion preparation and delivery. Secondary outcomes included the following: need for
respiratory therapy assistance, estimated cost of treatment sessions, and patient/caregiver
satisfaction.
Results: Five hundred seventy-five treatment sessions were enrolled (288 on nebulizers, 287 on
MDI-spacer). The nebulizer group had more male predominance and were slightly older
compared to the MDI-spacer group (male: 59% vs. 53% and mean age: 52 vs. 40 months14427761; fax: þ966 14427784.
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Replacing nebulizers by MDI-spacers 27respectively). The duration of treatment preparation and delivery was significantly lower in
the MDI-spacer group (2 min reduction in preparation time and 5 min reduction in delivery
time; p < 0.01). Caregivers mastered MDI-spacer use after an average of two observed ses-
sions, eliminating the need for respiratory therapy assistance during the hospital stay. Medica-
tion cost analysis showed savings in favor of MDI-spacer (cost reduction per 100 doses: 50% for
albuterol, 30% for ipratropium bromide, and 87% for ICSs). The patient satisfaction survey
showed “very good” to “excellent” levels in both groups.
Conclusions: Conversion to MDI-spacer for BDs and ICSs administration in hospitalized children
improve hospital resource utilization.
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Inhalational therapy represents the preferred mode of de-
livery for asthma medications. Nebulizers (for medications in
solution) and spacers (for metered-dose inhalers, MDIs) are
among the most widely used modalities. Several studies have
shown that MDI-spacers are as effective as, or better than,
nebulizers inaerosoldelivery inchildren [1e5].Nebulizers use
require a power supply, takemore time, are not conveniently
portable, are generally more expensive, require mainte-
nance, andneedmore supervision [6]. In contrast, spacers are
easier to use, require less effort and time, do not require dose
preparation or electricity for delivery, are portable, and
require lower medication doses compared to nebulizers [7].
Nebulizers can also have a significant impact on infec-
tion control. Use of nebulizers was associated with a major
outbreak of severe acute respiratory syndrome (SARS) in
Hong Kong in March 2003 [8].
In some hospitals, the use of nebulizers for hospitalized
children requires additional resources in terms of cost and
human resources because a respiratory therapist is required
to supervise treatment sessions. Despite all of these facts,
nebulizers are still widely used as the modality of choice to
administer bronchodilators (BDs) and inhaled corticoste-
roids (ICSs) to hospitalized children. Most asthma guide-
lines, including the recently published Saudi Initiative for
Asthma (SINA) guidelines, recommend the use of spacers
for children even younger than 6 yrs old [9,10].
2. Aim of the study
The aim of the study is to investigate the impact of con-
version to MDI-spacers to administer BDs and ICSs to hos-
pitalized children on the utilization of hospital resources
(treatment preparation and delivery time, need for respi-
ratory therapy assistance, and cost).
3. Materials and methods
This was a quality improvement project conducted to
evaluate the impact of inhalational device selection for
hospitalized children on the utilization of hospital re-
sources (treatment preparation and delivery time, need for
respiratory therapy assistance, and cost). The project was
conducted in a tertiary pediatric ward (King Faisal
Specialist Hospital & Research Centre) during AprileMay2013. The ultimate goal of this study was to come up with
an evidence-based practice policy for inhalational therapy
that minimizes unnecessary waste of hospital resources
without any negative impact on patient care. The study is
not intended to compare the pharmacological efficacy of
new interventions (both nebulizers and MDI-spacers are
licensed for use in children). The study was reviewed and
registered as a quality improvement project under the or-
ganization quality improvement board. Inclusion Criteria:
Hospitalized children requiring BDs and/or ICSs, age <14
years, and presence of caregiver. Exclusion Criteria: Un-
cooperative patients, sick patients requiring shift to
intensive care unit, or unavailable caregiver.
The project was conducted over a period of 6weeks. In the
first 2 weeks, data were gathered from all hospitalized chil-
dren receiving BDs and/or ICSs by nebulizers. This was fol-
lowed by a 2-week washout period during which training of
healthcare providers and operational changes were imple-
mented to enhance the conversion to MDI-spacer. In the last 2
weeks, data were gathered from hospitalized children after
conversion to MDI-spacer. Primary outcomes included the
mean time (in minutes) of medication preparation and de-
livery. Secondary outcomes included need for respiratory
therapy assistance, estimated cost of treatment sessions, and
patient/caregiver satisfaction. Device instruction was pro-
vided for caregivers involved in patient care.
The following data were collected during every treat-
ment session: preparation time, delivery time, medication
name, dosage, mode of delivery and oxygen flow rate
during nebulization therapy. An assessment sheet was used
to determine the minimum number of sessions supervised
by respiratory therapist required to ensure caregiver com-
petency in the use of MDI-spacer.
A patient/caregiver satisfaction survey was performed
as part of the quality assurance measurement that is
routinely collected by respiratory therapists in our hospital.
Medication and device cost were estimated based on the
information provided by hospital pharmacy and respiratory
therapy department, respectively. The medications that
were observed include bronchodilators (albuterol and
ipratropium bromide), inhaled corticosteroids (fluticasone
and budesonide) or a combination of long-acting broncho-
dilator and ICS (fluticasone/salmeterol). MDI-equivalent
dosages of BDs and ICSs solutions were developed (see
Table 1). Our target was to collect data from more than 100
treatment sessions in each part of the two project phases
(nebulizer phase and MDI-spacer phase) for a minimum of
Table 2 Demographic data of participants.
Nebulizer group MDI-spacer group
Sex
Male 170 (59%) 153 (53%)
Female 118 (41%) 134 (47%)
Age (months)
Range 46e58 35e44
Mean 52 40
Total 288 287
28 S.A. Alhaider et al.200 observational events. In addition to descriptive data
analysis, the Student t-test was used to compare the means
of preparation and delivery time between the two groups.
Statistical significance was set at p < 0.05.
4. Results
Five hundred seventy-five treatment sessions were enrolled
(288 on nebulizers, 287 on spacers). Table 2 shows the
demographic characteristics of both groups. The nebulizer
group had more male predominance (59%) compared to the
spacer group (53%). The average age of the children was 66
months. Children in the nebulizer group were slightly older
(mean age 52 months; range: 2e165 months) compared to
the spacer group (mean age 40 months; range: 9e168
months). The prescribed medications were the following:
albuterol (45%), ICS (20%), combinations (31%), ipratropium
bromide (4%), and others (4%).
In the nebulizer group, the mean time for treatment
preparation was 2.05 min (95th% CI: 1.45e2.15 min), and
the mean time for treatment delivery was 9.39 min (95th%
CI: 9.06e10.12). In the MDI-spacer group, the mean time
for treatment preparation was 0.3 min (95th% CI:
0.03e0.5 min), and the mean time for treatment delivery
was 4.38 min (95th% CI: 4.2e4.56 min) (see Table 3). These
results indicate that replacing nebulizers by MDI-spacers
shortens the time for medication preparation time by 98%
and delivery time by 48% (2 min difference for preparation
time and 5 min for delivery time; p < 0.01).
Caregivers mastered MDI-spacer use after an average of
2 supervised sessions. As a result, conversion to MDI-spacer
will lead to more independent treatment administration by
patients/caregivers. This can have a significant impact on
resource utilization in organizations that mandate that all
nebulizer sessions be supervised by a respiratory therapist.
Patient satisfaction survey showed stable “very good” to
“excellent” levels in both phases of the study. Medication
cost reduction analysis showed that cost reduction per 100
doses as the following: 50% for albuterol, 30% for ipra-
tropium bromide, and 87% for ICSs in favor of MDI-spacer
(taking into account cost of medication, spacer, and
nebulization kit).Table 1 MDI equivalent dosage of BDs and ICSs solutions.
Medication Solution
(nebulizer)
dosage
MDI equivalent dosage
Albuterol 2.5 mg 3e5 puffsa
Albuterol 5.0 mg 5e10 puffsa
Ipratropium
bromide
0.25 mg 2 puffs
Ipratropium
bromide
0.5 mg 4 puffs
Budesonide 0.25 mg Fluticasone (125 mcg)
2 puffs
Budesonide 0.5 mg Fluticasone (250 mcg)
2 puffs
a The range provided for MDI doses need to be adjusted based
on (response: side-effect) assessment.5. Discussion
This study demonstrates the important role of quality
improvement projects that implement evidence-based
practice to optimize the utilization of hospital resources.
The study results indicate the need for hospital policy
modification to enhance conversion to MDI-spacer as the
delivery method of choice for BDs and ICSs whenever
applicable for hospitalized children. We believe that this
will lead to better utilization of hospital resources without
negatively affecting the pharmacological effect of medi-
cations. In fact, this simple practice change will lead to
wiser utilization of respiratory therapists’ time and efforts,
which can be utilized for other important aspects of patient
care. This is of extreme importance, especially with the
significant shortage in respiratory therapists across hospi-
tals globally. Cost savings is also expected as a result of the
lower cost of medications, elimination of the need for
nebulizer machines and disposable nebulizer kits, preven-
tion of unnecessary use of oxygen treatment, and, more
importantly, reducing the need for the cost of respiratory
therapist overtime shifts. Although these savings are
theoretically plausible, there is a lack of solid evidence to
confirm those assumptions. We note that conversion to MDI-
spacer might raise the concern of increasing costs due to
spacer expenses, but this might not be a valid concern
because these devices can be provided for patients for
long-term use.
Minimizing the use of nebulizers might have health
benefits related to decreasing the airborne spread of in-
fectious agents, which have significant effects in inpatient
care in pediatric hospitals [8]. This might have significant
“infection control” impact. However, to our knowledge this
has not been investigated in a pediatric population.Table 3 Summary of preparation and delivery times for
nebulizer and MDI-spacer groups.
Nebulizer
group
MDI-spacer
group
Time
difference
Preparation
time
2.05 min
(95th% CI:
1.45e2.15)
0.3 min
(95th% CI:
0.03e0.5)
2 min
(p < 0.01)
Delivery
time
9.39 min
(95th% CI:
9.06e10.12)
4.38 min
(95th% CI:
4.2e4.56)
5 min
(p < 0.01)
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MDI-spacers and nebulizers for bronchodilator administra-
tion in the emergency department have resulted in similar
clinical responses, with shorter duration of stay, lower
incidence of tachycardia, and even lower rate of admis-
sions. In one study, 168 infants (aged 2e24 months) were
randomized in a double blind trial comparing MDI-spacer- to
nebulizer-administered albuterol for wheezing episodes in
the emergency department [11]. Patients in the spacer
group had a significantly lower admission rate (5% versus
20% in the nebulizer group), received fewer treatments,
had a lower mean increase in heart rate and were less likely
to receive steroids. Lower admission rates in the spacer
group were found primarily in children with more severe
asthma exacerbation [11]. Another randomized, double-
blind, placebo-controlled trial in an emergency depart-
ment at a children’s hospital included children 1e4 years of
age with moderate to severe acute asthma. The spacer was
as effective as the nebulizer in terms of clinical score,
respiratory rate, and oxygen saturation but produced a
greater reduction in wheezing (P Z 0.03). Heart rate
increased to a greater degree in the nebulizer group (11.0/
min vs. 0.17/min for spacer, p < 0.01). Fewer children in
the spacer group required admission (33% vs. 60% in the
nebulizer group, P Z 0.04, adjusted for sex). No differ-
ences were observed in rates of tremor or hyperactivity
[12]. Interestingly, this study showed cost savings in spacer
group. Such cost benefits have been reported in studies of
American adults, documenting a 30%e50% annual cost
savings for asthma therapy with substitution of spacers for
nebulizers [13e16]. A meta-analysis and systematic review
showed that patients who received beta-agonists by MDI-
spacer showed a significant decrease in admission rate
compared with those by nebulizer (OR, 0.42; 95% CI,
0.24e0.72; P Z 0.002); this decrease was even more sig-
nificant among children with moderate to severe exacer-
bations (OR, 0.27; 95% CI, 0.13e0.54; P Z 0.0003).
Additionally, measures of severity (eg, clinical score)
significantly improved in the group that received beta-
agonists by MDI-spacer in comparison to those who
received nebulizer treatment (standardized mean differ-
ence, 0.44; 95% CI, 0.68 to 0.20; P Z 0.0003) [17].
Conversion to MDI-spacer might encounter difficulties
such as lack of awareness of healthcare practitioners, pa-
tient and/or caregiver disbelief that nebulizers are more
effective, shortage of the proper size and type of spacers,
and need for effective patient education to ensure proper
device use. In a Canadian study, a national survey on bar-
riers to MDI-spacer use in pediatric emergency departments
revealed that MDI-spacer are infrequently used to treat
patients with acute asthma in Canadian pediatric emer-
gency departments despite the fact that most emergency
staff believe that they are effective. The largest perceived
barriers to MDI-spacer implementation include concerns
regarding safety and costs, feasibility of providing and
sterilizing spacers, and parental expectations for use of
nebulizers. Other barriers included staff beliefs regarding
the effectiveness of MDI-spacer, changes in nursing work-
load, and lack of a physician champion for change [18]. A
report on US children’s hospital’s strategy to implement
conversion to MDI-spacer showed increase spacer use from
25% to 77% among all non-intensive-care patients receivingalbuterol and from 10% to 79% among patients with asthma
(p < 0.001) [19]. The strategy includes the following 4
distinct interventions to plan and implement this conver-
sion program: literature review, product selection, policy
and operational changes, and staff training.
Our study showed no change in patient and/or caregiver
satisfaction after conversion to MDI-spacer. In an Australian
study, the majority of parents (84%) found it ’easy’ or ’very
easy’ to use the spacer, and 85% reported that they
intended to use the spacer at home. The majority of chil-
dren (82%) said that they preferred using spacers because it
was quicker (29%) or easier to use (53%) [20]. In another
study of young patients, 86% of children and 85% of parents
preferred the spacer [12].
6. Conclusions
Conversion to MDI-spacer for the administration of bron-
chodilators and inhaled corticosteroids to hospitalized
children led to a reduction in treatment preparation and
delivery time and enabled early independent administra-
tion by patient/caregiver in addition to a potential reduc-
tion in medication cost. This quality improvement project
indicates that the selection of inhalational device can have
a major impact on resource utilization in hospitals. Further
studies are required to investigate the impact of such
strategies on hospital length of stay and in different set-
tings, eg, the emergency department.
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